Home / MSCL.TO : TSX

AI Analysis Fundamentals Valuation Video Analysis News Similar

AI Analysis

How does MSCL.TO make money? Does MSCL.TO have pricing power? What's the Earnings Whisper? Will MSCL.TO profit more as the business scales? What is MSCL.TO's management track record? Is MSCL.TO's current price justified?

Satellos Bioscience Inc.

CAD 13.51 +$5.11 (+60.83%)

TSX · 14 Sep 2026 19:59 UTC

Previous Close

CAD 13.2

Day Range

CAD 13.51CAD 14

Year Range

CAD 7.32CAD 18.98

Market Cap

281.43M

AVG Volume

19.61K

Trailing/Forward PE

-4.9/-

PEG ratio

27.08

Dividend Yield

Next Earnings Date

2026-11-12

Primary Exchange

Toronto Stock Exchange

Net Income (USD)

MSCL.TO Net Income (USD) by quarter
Period	Net Income (USD)
26 Q2	-12.09M
26 Q1	-9.61M
25 Q4	-7.42M
25 Q3	-5.82M
25 Q2	-5.61M
25 Q1	-6.16M
24 Q4	-6.11M
24 Q3	-9.05M
24 Q2	-6.04M
24 Q1	-6.91M

Operating Income (USD)

MSCL.TO Operating Income (USD) by quarter
Period	Operating Income (USD)
26 Q2	-12.16M
26 Q1	-10.04M
25 Q4	-7.76M
25 Q3	-5.97M
25 Q2	-6.37M
25 Q1	-6.48M
24 Q4	-7.81M
24 Q3	-5.06M
24 Q2	-6.68M
24 Q1	-8.26M

EBITDA (USD)

MSCL.TO EBITDA (USD) by quarter
Period	EBITDA (USD)
26 Q2	-12.16M
26 Q1	-10.04M
25 Q4	-7.76M
25 Q3	-5.96M
25 Q2	-6.45M
25 Q1	-6.48M
24 Q4	-6.09M
24 Q3	-9.04M
24 Q2	-6.03M
24 Q1	-6.91M

Cash Flows (USD)

MSCL.TO Cash Flows (USD) by quarter
Period	Cash Flows (USD)
26 Q2	-7.83M
26 Q1	-9.43M
25 Q4	-7.38M
25 Q3	-4.13M
25 Q2	-4.85M
25 Q1	-7.37M
24 Q4	-7.81M
24 Q3	-4.38M
24 Q2	-5.66M
24 Q1	-7.13M

EPS (USD)

MSCL.TO EPS (USD) by quarter
Period	EPS (USD)
26 Q2	-0.57
26 Q1	-0.52
25 Q4	-0.48
25 Q3	-0.41
25 Q2	-0.39
25 Q1	-0.45
24 Q4	-0.44
24 Q3	-0.96
24 Q2	-0.64
24 Q1	-0.74

Expenses (USD)

MSCL.TO Expenses (USD) by quarter
Period	Expenses (USD)
26 Q2	11.91M
26 Q1	9.54M
25 Q4	8.57M
25 Q3	5.86M
25 Q2	4.54M
25 Q1	4.45M
24 Q4	7.56M
24 Q3	4.95M
24 Q2	6.68M
24 Q1	8.28M

Cash & Debt (USD)

MSCL.TO Cash & Debt (USD) by quarter
Period	Cash & Debt (USD)
26 Q2	61.74M
26 Q1	69.96M
25 Q4	27.66M
25 Q3	34.61M
25 Q2	38.22M
25 Q1	41.19M
24 Q4	69.85M
24 Q3	23.42M
24 Q2	27.7M
24 Q1	33.17M

Debt ratios

MSCL.TO Debt ratios by quarter
Period	Debt ratios
26 Q2	1.72
26 Q1	2.32
25 Q4	1.04
25 Q3	1.39
25 Q2	1.36
25 Q1	1.49
24 Q4	2.49
24 Q3	0.82
24 Q2	1.2
24 Q1	1.58

Return on Capital

MSCL.TO Return on Capital by quarter
Period	Return on Capital
26 Q2	-20.21%
26 Q1	-13.59%
25 Q4	-26.74%
25 Q3	-17.12%
25 Q2	-14.62%
25 Q1	-14.78%
24 Q4	-9%
24 Q3	-43.95%
24 Q2	-20.7%
24 Q1	-20.03%

Shares Outstanding

MSCL.TO Shares Outstanding by quarter
Period	Shares Outstanding
26 Q2	20.83M
26 Q1	18.44M
25 Q4	15.46M
25 Q3	13.94M
25 Q2	14.27M
25 Q1	13.82M
24 Q4	13.82M
24 Q3	9.42M
24 Q2	9.4M
24 Q1	9.4M

Book Value Per Share (USD)

MSCL.TO Book Value Per Share (USD) by quarter
Period	Book Value Per Share (USD)
26 Q2	2.87
26 Q1	3.84
25 Q4	1.79
25 Q3	2.44
25 Q2	2.69
25 Q1	3.02
24 Q4	4.91
24 Q3	2.19
24 Q2	3.1
24 Q1	3.67

Total Assets (USD)

MSCL.TO Total Assets (USD) by quarter
Period	Total Assets (USD)
26 Q2	65.66M
26 Q1	75.28M
25 Q4	31.83M
25 Q3	37.5M
25 Q2	41.12M
25 Q1	44.37M
24 Q4	73.02M
24 Q3	24.21M
24 Q2	33.19M
24 Q1	38.26M

Free Cash Flow Yield

MSCL.TO Free Cash Flow Yield by quarter
Period	Free Cash Flow Yield
Sep 26	-14.36%
Sep 26	-14.69%
Sep 26	-15.54%
Aug 26	-16.05%
Aug 26	-14.25%
Aug 26	-14.5%
Aug 26	-14.2%
Jul 26	-14%
Jul 26	-14.13%
Jul 26	-15.95%
Jul 26	-14.63%
Jul 26	-18.21%
Jun 26	-21.34%
Jun 26	-26.63%
Jun 26	-26.76%
Jun 26	-26.08%
May 26	-20.94%
May 26	-22.19%
May 26	-21.19%
May 26	-20.45%
May 26	-19.63%
Apr 26	-21.5%
Apr 26	-17.63%
Apr 26	-23.46%
Apr 26	-25.88%
Mar 26	-27.94%
Mar 26	-23.47%
Mar 26	-21.64%
Mar 26	-14.49%
Feb 26	-13.88%
Feb 26	-15.19%
Feb 26	-14.98%
Feb 26	-14.75%
Jan 26	-15.24%
Jan 26	-17.19%
Jan 26	-21.82%
Jan 26	-24.04%
Jan 26	-28.3%
Dec 25	-29.07%
Dec 25	-28.91%
Dec 25	-29.28%
Dec 25	-29.38%
Nov 25	-28.04%
Nov 25	-29.11%
Nov 25	-27.36%
Nov 25	-29%
Oct 25	-25.91%
Oct 25	-27.69%
Oct 25	-24.96%
Oct 25	-24.93%
Oct 25	-24.83%
Sep 25	-32.11%
Sep 25	-33.24%
Sep 25	-31.42%
Sep 25	-31.85%
Aug 25	-34.81%
Aug 25	-35.62%
Aug 25	-35.6%
Aug 25	-36.69%
Aug 25	-38.11%
Jul 25	-37.19%
Jul 25	-35.35%
Jul 25	-35.87%
Jul 25	-33.89%
Jun 25	-25.97%
Jun 25	-27.39%
Jun 25	-27.9%
Jun 25	-26.43%
May 25	-23.18%
May 25	-19.82%
May 25	-23.91%
May 25	-22.83%
May 25	-22.83%
Apr 25	-23.91%
Apr 25	-23.54%
Apr 25	-23.91%
Apr 25	-23.18%
Mar 25	-25.01%
Mar 25	-25.98%
Mar 25	-21.74%
Mar 25	-23.81%
Feb 25	-22.73%
Feb 25	-25.65%
Feb 25	-27.4%
Feb 25	-25.32%
Jan 25	-24.1%
Jan 25	-22.99%
Jan 25	-24.4%
Jan 25	-23.53%
Jan 25	-22.73%
Dec 24	-22.41%
Dec 24	-23.2%
Dec 24	-20.33%
Dec 24	-24.34%
Nov 24	-28.17%
Nov 24	-26.29%
Nov 24	-23.2%
Nov 24	-23.2%
Nov 24	-23.76%
Oct 24	-24.34%

Price to Book

MSCL.TO Price to Book by quarter
Period	Price to Book
Sep 26	2.54
Sep 26	2.48
Sep 26	2.35
Aug 26	2.27
Aug 26	2.56
Aug 26	2.51
Aug 26	2.57
Jul 26	2.6
Jul 26	2.58
Jul 26	2.29
Jul 26	2.49
Jul 26	2
Jun 26	4.01
Jun 26	3.21
Jun 26	3.2
Jun 26	3.28
May 26	4.08
May 26	3.85
May 26	4.04
May 26	4.18
May 26	4.36
Apr 26	3.98
Apr 26	4.85
Apr 26	3.65
Apr 26	3.3
Mar 26	2.54
Mar 26	3.03
Mar 26	3.28
Mar 26	4.9
Feb 26	5.12
Feb 26	4.68
Feb 26	4.74
Feb 26	4.82
Jan 26	4.66
Jan 26	4.13
Jan 26	3.25
Jan 26	2.95
Jan 26	2.51
Dec 25	2.19
Dec 25	2.2
Dec 25	2.17
Dec 25	2.17
Nov 25	2.27
Nov 25	2.19
Nov 25	2.33
Nov 25	2.19
Oct 25	2.46
Oct 25	2.3
Oct 25	2.55
Oct 25	2.55
Oct 25	2.56
Sep 25	1.88
Sep 25	1.82
Sep 25	1.93
Sep 25	1.9
Aug 25	1.74
Aug 25	1.7
Aug 25	1.7
Aug 25	1.65
Aug 25	1.59
Jul 25	1.63
Jul 25	1.71
Jul 25	1.69
Jul 25	1.79
Jun 25	1.42
Jun 25	1.34
Jun 25	1.32
Jun 25	1.39
May 25	1.59
May 25	1.86
May 25	1.54
May 25	1.61
May 25	1.61
Apr 25	1.54
Apr 25	1.56
Apr 25	1.54
Apr 25	1.59
Mar 25	4.39
Mar 25	4.23
Mar 25	5.05
Mar 25	4.61
Feb 25	4.83
Feb 25	4.28
Feb 25	4.01
Feb 25	4.34
Jan 25	4.56
Jan 25	4.78
Jan 25	4.5
Jan 25	4.67
Jan 25	4.83
Dec 24	3.4
Dec 24	3.29
Dec 24	3.75
Dec 24	3.13
Nov 24	2.71
Nov 24	2.9
Nov 24	3.29
Nov 24	3.29
Nov 24	3.21
Oct 24	3.13

No video analysis for this stock yet. Request one from our team.

News: MSCL.TO

globenewswire.com · 17 Jun 2026

Satellos Bioscience Announces Results of Annual Meeting of Shareholders

TORONTO, June 17, 2026 (GLOBE NEWSWIRE) -- Satellos Bioscience Inc. (NASDAQ: MSLE, TSX: MSCL) ("Satellos" or the "Company"), a clinical-stage biotechnology company developing life-improving medicines to treat degenerative muscle diseases, announced today the results of its Annual Meeting of Shareholders held June 17, 2026 (the "Meeting").

AI Analysis

Satellos Bioscience Inc.

Video analysis: MSCL.TO

News: MSCL.TO

Satellos Bioscience Announces Results of Annual Meeting of Shareholders

Similar companies